Despite the drug blockading the PD-1/PD-L1 pathways has been shown exciting therapeutic benefits for patients with advanced NSCLC, less than 20% NSCLC patients could benefit for these novel agents [23–25], suggesting an unmet need for identification of patients in this type of immunotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.